REPORTING FROM ACC 18
In patients with severe renal dysfunction given idarucizumab, “be alert for a recurrent bleed,” which could require a second dose of idarucizumab, Dr. Eikelboom suggested.
SOURCE: Eikelboom JW et al. ACC 18, Abstract 1231M-11.
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
TORONTO – Which comes first: the acute kidney injury or the venous thromboembolism?
Reduced stroke risk, no increase in bleeding in atrial fibrillation and advanced chronic kidney disease.
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
